Open-House-Biologika-Rabattverträge 2025-01 - Infliximab

Summary

The tender concerns the supply of infliximab medicines and the conclusion of medicine rebate agreements under an open-house procedure. The contract is split into two lots, the terms are the same for all participants, no individual negotiations are held and no exclusivity is granted. The bidder must be a pharmaceutical entrepreneur and must be able to show that it is entitled to place the relevant medicines on the market. The contract term is up to 24 months from 01/04/2025 and ends no later than 31/03/2027. Joining is possible throughout the contract period.